Pipeline

Wholly-owned
US
Wholly-owned
Global
Collaboration

Product (Partner)
Phase
Binimetinib (Ono, PF**) Indication: Cancer
Target: MEK
   NDA
Encorafenib (Ono, PF**) Indication: Cancer
Target: BRAF
   NDA
Danoprevir (Roche) Indication: Hepatitis C
Target: NS3 Protease
   NDA
Selumetinib (AstraZeneca) Indication: Cancer and NF1
Target: MEK
  Phase 3*
Ipatasertib (Genentech) Indication: Cancer
Target: AKT
  Phase 3*
Larotrectinib (Loxo Oncology) Indication: Cancer
Target: PanTrk
  Phase 2*
Tucatinib (Cascadian Therapeutics) Indication: Breast Cancer
Target: HER-2
  Phase 2*
Varlitinib (ASLAN) Indication: Gastric and Breast Cancer
Target: Pan-HER
  Phase 2*
ARRY-797 Indication: LMNA A/C-related DCM
Target: p38
 Phase 2
Motolimod (Celgene) Indication: Cancer
Target: TLR
 Phase 2
Prexasertib (Eli Lilly) Indication: Cancer
Target: Chk-1
 Phase 2
ARRY-382 Indication: Cancer
Target: CSF1R
Phase 1/2
GDC-0575 (Genentech) Indication: Cancer
Target: Chk-1
Phase 1
LOXO-292 (Loxo Oncology) Indication: Cancer
Target: Ret
Phase 1
LOXO-195 (Loxo Oncology) Indication: Cancer
Target: Trk
Phase 1
*Registration Trial
**Pierre Fabre